Home » Agenda » Day 1

Day 1

P​HARMA ​PATIENT ACCESS WORLD CONGRESS 2025 EUROPE

Improving Patient Access for Better Health Outcomes and Quality of Life

Copthorne Tara Hotel London Kensington​, London, UK, London, United Kingdom

Day 1 - Wednesday 11th June 2025

TRENDS & STRATEGIES IN PATIENT ACCESS

  • Ensuring that patients can access products in a timely and affordable manner.
  • Need to have access to data and insights early and often to make informed decisions about how pharma and biotech companies get their drugs to patients
  • Digitizing healthcare to improve patient access
  • Demonstrating cost-effectiveness of the product
  • What is most important to patients?

Moderator:

Panelists:

  • Addressing the shifting regulations
  • Payer revenue optimization strategies
  • The need for a 360-degree perspective across the drug development life cycle,
  • The promise of real-world data (RWD) to address complex challenges
  • How can we seize this opportunity to improve patient access to medicines?
  • Assessing the impact of the regulation on national HTAs
  • Strategic implications for health technology developers
  • Its influence on price and reimbursement negotiations.
  • Meeting growing demands for rigorous data requirements
  • Understanding of increasingly diverse environment
  • Strategic and adaptive approach in navigating complexities of different ecosystem
  • Breaking down silo mentality
  • Harmonizing access needs and aligning strategies at an early stage
  • Advancing landscape and drivers in medical devices
  • The importance of early and continuous stakeholder engagement
  • How multi-stakeholder collaboration streamlines the path to market and guarantees that medical devices are thoroughly designed, tested, and deployed.
  • Significance of patient-centered design on market access
  • Prioritizing patient needs and preferences to enhance patient outcomes
  • Adopting tech-powered tools that enables to have a more direct relationship with HCPs and the patients they serve
  • Innovative technologies that make patient-focused approaches scalable and efficient
  • Innovative steps to improve access strategy by interacting with PAGs
  • Best practices while interacting with PAGs in order to guarantee efficient cooperation and patient needs alignment.
  • Integrating patient insights to improve the acceptance and relevance of health innovations
  • Overcoming challenges interacting with PAGs

REGULATORY & COMMERCIALISATION

  • Key trends that will affect the European biopharmaceutical market access landscape
  • Impact of both the EU’s industrial pharma policy and the health technology assessment (HTA) landscape
  • Overcoming the increasing constraints on government healthcare budgets
  • Fundamental policy changes affecting the industry
  • Breaking down silos for comprehensive strategy to anticipate challenges and opportunities in both short and long term
  • Addressing urgent policy changes and stakeholder concerns while planning for the future
  • Integrating patient-centricity into the broader patient access strategy
  • Harmonisation imperative for sustained growth
  • Varying framework in place to improve patient access to innovative medicines
  • Considerations for a suitable pharmaceutical regulatory and clinical framework
  • How regulation can help to unlock the potential of innovative medicines
  • Streamlined regulatory framework bringing breakthroughs to patients faster
  • Improving provider schedules and allowing patients to schedule their own appointment to improve access and patient satisfaction.
  • Using technology to improve care coordination
  • Streamlining processes to reduce inefficiencies, delays and revenue loss
  • Facilitating patient engagement with the use of patient portals, apps and educational resources
  • Value-based approach to affordability
  • Varying healthcare needs and affordability challenges
  • Programmes that provide patients financial support to help fund therapy expenditures
  • Significant pitfalls associated with programmes design
  • Addressing the payer activation and reimbursement challenges
  • The impact of regulatory roadblocks and competition
  • Overcoming the issue on inadequate market adoption by HCPs
  • Patient engagement and adoption challenges
  • Encourage shared decision-making to help patients feel more empowered and make informed choices.
  • Open and clear communication between patients and providers to build trust and understanding.
  • Educate patients to ensure patients understand their treatment plan, medications, and diagnosis
  • Use innovative technology to improve the patient experience
  • Ensuring that patients have access to the right treatments at the right time and fair price that aligns with the effectiveness of a drug in treating disease
  • Establishing pricing and reimbursement sustainability for both the pharmaceutical manufacturer and the healthcare payer
  • Incorporating patient input to ensure that their drugs address the specific needs, preferences, and quality of life concerns of patients.
  • Collaborative, patient-centric care approach that enhances the quality of life for patients with complex chronic conditions
  • Removing barriers to treatment and improving patient access to essential therapies.
Update cookies preferences
Scroll to Top